Vyant Bio, Inc. VYNT
We take great care to ensure that the data presented and summarized in this overview for Vyant Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in VYNT
Top Purchases
Top Sells
About VYNT
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
Insider Transactions at VYNT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 17
2023
|
Joanna Horobin Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,526
+24.56%
|
-
|
|
Jan 17
2023
|
R John Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,368
+15.45%
|
-
|
|
Jan 17
2023
|
Geoffrey E. Harris Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,712
+22.42%
|
-
|
|
Jan 17
2023
|
Paul R. Hansen Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,032
+2.57%
|
-
|
|
Nov 18
2022
|
Geoffrey E. Harris Director |
SELL
Open market or private sale
|
Direct |
765
-2.6%
|
$765
$1.34 P/Share
|
|
Oct 17
2022
|
R John Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,290
+7.83%
|
-
|
|
Oct 17
2022
|
Paul R. Hansen Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,653
+1.02%
|
-
|
|
Oct 17
2022
|
Geoffrey E. Harris Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,841
+12.79%
|
-
|
|
Oct 17
2022
|
Joanna Horobin Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,285
+15.48%
|
-
|
|
Jul 18
2022
|
Paul R. Hansen Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,335
+0.58%
|
-
|
|
Jul 18
2022
|
R John Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,696
+4.99%
|
-
|
|
Jul 18
2022
|
Geoffrey E. Harris Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,141
+8.87%
|
-
|
|
Jul 18
2022
|
Joanna Horobin Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,092
+11.27%
|
-
|
|
Apr 18
2022
|
Marcus Boehm Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,281
+11.42%
|
-
|
|
Apr 18
2022
|
Geoffrey E. Harris Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,157
+8.31%
|
-
|
|
Apr 18
2022
|
R John Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,944
+4.45%
|
-
|
|
Apr 18
2022
|
Paul R. Hansen Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,640
+0.49%
|
-
|
|
Apr 18
2022
|
Joanna Horobin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,796
+10.89%
|
-
|
|
Mar 30
2022
|
R John Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
68,322
+33.65%
|
-
|
|
Mar 30
2022
|
Geoffrey E. Harris Director |
BUY
Grant, award, or other acquisition
|
Direct |
43,478
+45.64%
|
-
|